A study to compare the effects of two drug regimes Terlipressin plus Albumin Vs Midodrine,Octreotide plus Albumin in the treatment of a fatal complication of Chronic Liver Disease which effects the Kidney function (Hepatorenal Syndrome)

A Randomised Control Trial to compare efficacy of Terlipressin plus Albumin vs Midodrine, Octreotide plus Albumin in the Treatment of Hepatorenal Syndrome . - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064877

Enrollment

Registered

2024-03-28

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K767- Hepatorenal syndrome

Interventions

Intervention1: TERLIPRESSIN PLUS ALBUMIN: 1)INJ ALBUMIN 20% ONCE DAILY ROUTE Intravenous duration 7 days 2)INJ TERLIPRESSIN 1MG 6-8 JOURLY ROUTE INTRAVENOUS DURATION 7 DAYS Control Intervention1: MIDO

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patient 18 years or older of both sexes 2)Patients diagnosed with HRS

Exclusion criteria

Exclusion criteria: 1)Contraindications to Terlipressin 2)Patients diagnosed with chronic kidney disease 3)Child Pugh Score more than 13 4)Ongoing shock or uncontrolled bacterial infection 5)Current or recent treatment with nephrotoxic drugs 6)Presence of cardiovascular diseases and any extra hepatic diseases that could affect the short term prognosis

Design outcomes

Primary

Measure	Time frame
Fifty Percentage reduction in serum creatinine or value less than 1.5mg/dl on day 7Timepoint: Day 7	—

Secondary

Measure	Time frame
Daily Urine output and MAP Alternate days Serum Sodium, Potassium,Urea PT INR ON DAY 7Timepoint: Daily, alternate days and seventh day	—

Countries

India

Contacts

Public ContactDr Karam Romeo Singh

Regional Institute of Medical Sciences,Imphal

karamdr@gmail.com6909364005

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026